Immuneering (IMRX) Non Operating Investment Income (2021 - 2022)

Immuneering (IMRX) posted quarterly Non Operating Investment Income of $112353.0 for Q4 2022, up 353.86% year-over-year from $24755.0 in Q4 2021, and up 187.44% quarter-over-quarter from $39088.0 in Q3 2022.

Immuneering (IMRX) Non Operating Investment Income (2021 - 2022) Analysis & Trends

Immuneering's Non Operating Investment Income history runs 2 years deep, the most recent figure standing at $112353.0 for Q4 2022.

  • In Q4 2022, Non Operating Investment Income rose 353.86% year-over-year to $112353.0; the TTM figure through Dec 2022 stood at $18889.0 (changed N/A YoY), while the FY2022 annual figure was $18889.0, up 138.54% from the prior year.
  • Non Operating Investment Income for Q4 2022 stood at $112353.0, up from $39088.0 in the prior quarter.
  • The five-year high for Non Operating Investment Income was $112353.0 in Q4 2022, with the low at -$118386.0 in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Immuneering 327.37 Mn 327.37 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2022 112,353.00
Dec 31, 2022 112,353.00
Sep 30, 2022 39,088.00
Sep 30, 2022 39,088.00
Jun 30, 2022 -14,166.00
Jun 30, 2022 -14,166.00
Mar 31, 2022 -118,386.00
Mar 31, 2022 -118,386.00
Dec 31, 2021 -44,258.00
Dec 31, 2021 -44,258.00
Sep 30, 2021 -4,751.00
Sep 30, 2021 -4,751.00